Vijaya Diagnostic Centre
- Market cap
- ₹ 14,387 Cr.
- P/E
- 76.3x
- P/B
- 14.95x
- 52-week range
- 848 – 1,593.6
- ROE
- 20%
- ROCE
- 21%
- Dividend yield
- 0.1%
- Debt / equity
- 0.44
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- NSE, BSE
About
Vijaya Diagnostic Centre Limited is an India-based company, which is engaged in the business of providing a range of diagnostic services, spanning pathological investigations, basic and high-end radiology, nuclear medicine, and related healthcare services. It operates through the Diagnostic Services segment. It offers laboratory services and radiology services. Its services include clinical pathology, microbiology, hematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, computerized tomography (CT) scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine, and MRI-3T. It operates approximately 160 diagnostic centers in 25 cities spread across India. Its clinical pathology includes liver function test (LFT-A), creatine kinase (CPK) test, and thyroid profile test. It offers various health checkups, which include general wellness, women's care, gynecology packages, and lifestyle.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Vijaya Diagnostic Centre against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)76.3 against a typical 20.5: pricier than most peers (1st = cheapest).30th of 34
- Sales growth+22.9% against a typical +19.1% from a year earlier.12th of 31
- Profit growth+35.9% against a typical +25.2% from a year earlier.7th of 24
- Share price, 3 months+5.2% against a typical −7.5%.7th of 33
- Size₹ 14,387.1 Cr. market value against a typical ₹ 83 Cr. (1st = largest).2nd of 34
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil B(Issuer Not Cooperating) | Stable | 25 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 25 Jun 2026 | Rating action | Crisil B(Issuer Not Cooperating) | — | CRISIL | ₹ 40 Cr. |
Research by Minerva Capital Research Solutions
Our research team's work on Vijaya Diagnostic CentreAlso covered in
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 6 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 7 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 4 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 28 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 12 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 133 | 155 | 156 | 183 | 169 | 173 | 188 | 202 | 205 | 219 | 231 |
| Expenses | 82 | 80 | 92 | 95 | 107 | 102 | 104 | 115 | 120 | 119 | 124 | 132 |
| Operating Profit | 57 | 52 | 63 | 61 | 76 | 67 | 69 | 74 | 82 | 86 | 96 | 99 |
| OPM % | 41% | 39% | 41% | 39% | 42% | 40% | 40% | 39% | 41% | 42% | 44% | 43% |
| Other Income | 7 | 3 | 3 | 4 | 5 | 5 | 5 | 7 | 6 | 5 | 2 | 9 |
| Interest | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 9 | 9 | 11 |
| Depreciation | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 | 24 | 25 |
| Profit before tax | 45 | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 | 64 | 71 |
| Tax % | 25% | 25% | 23% | 25% | 26% | 24% | 26% | 26% | 25% | 26% | 25% | 25% |
| Net Profit | 34 | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 | 48 | 53 |
| EPS in Rs | 3.26 | 2.53 | 3.27 | 3.06 | 4.1 | 3.43 | 3.4 | 3.76 | 4.21 | 4.2 | 4.66 | 5.16 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 17%
- 3 Years
- 21%
- TTM
- 20%
- 10 Years
- —
- 5 Years
- 15%
- 3 Years
- 27%
- TTM
- 24%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 46%
- TTM
- —
- 10 Years
- —
- 5 Years
- 20%
- 3 Years
- 19%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Vijaya Diagnostic Centre | ₹ 1,442.00 | ₹ 14,387 Cr. | 76.3x | 15x | 20% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Sura Surendrana Reddy
- Executive Chairman of the Board, Founder
- Sura Suprita Reddy
- Chief Executive Officer, Managing Director, Executive Director
- Narasimha Raju K. A.
- Chief Financial Officer
- Ankit Shah
- Chief Financial Officer
- Venkata Siva Rama Raju Vegesna
- Chief Operating Officer
- Naga Vasudha Tadepalli
- Compliance Officer, Company Secretary
- Sunil Chandra Kondapally
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.